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Abstract: The asymptomatic course of Chlamydia trachomatis (CT) infections can result in
underestimated CT lifetime prevalence. Antibody testing might improve this estimate. We assessed
CT antibody positivity and predictive factors thereof in the Netherlands Chlamydia Cohort Study.
Women who had ≥1 CT Nucleic Acid Amplification Test (NAAT) in the study (2008–2011) and who
provided self-reported information on NAATs were tested for CT major outer membrane protein
specific IgG in serum (2016). CT antibody positivity was assessed and predictive factors were
identified using multivariable logistic regressions, separately for CT-positive women (≥1 positive
NAAT or ≥1 self-reported positive CT test) and CT-negative women (negative by study NAAT and
self-report). Of the 3,613 women studied, 833 (23.1%) were CT -positive. Among the CT-negative
women, 208 (7.5%, 95% CI 6.5–8.5) tested positive for CT antibodies. This increased CT lifetime
prevalence with 5.8% (95% CI 5.0–6.5). Among women with a CT-positive history, 338 (40.6%,
95% CI 38.5–44.1) tested positive. Predictive factors for antibody positivity related to lower social
economic status, sexual risk behavior, multiple infections, higher body mass index, and non-smoking.
CT antibody testing significantly increased the lifetime prevalence. Combining NAAT outcomes,
self-reported positive tests, and antibody testing reduced misclassification in CT prevalence estimates.
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1. Introduction
Disease monitoring and proper evaluation of Chlamydia trachomatis (CT) control efforts are
important and require accurate estimates of current and lifetime CT prevalence [1]. This is, however,
challenging given the asymptomatic nature of the CT infection. Current prevalence estimates and our
understanding of CT related complications are primarily based on studies that measure current (vaginal)
infections by using nucleic acid amplification tests (NAATs) [2,3]. These tests have a high sensitivity
to detect CT [4]. However, CT infections are asymptomatic in up to 70% of the cases in women [5].
Therefore, a considerable part of these infections might go unnoticed and thus remain undetected [2,6].
Presumably, an underestimation of the CT lifetime prevalence is the result [6,7]. Furthermore, estimating
the proportion of infected women that later experiences CT related complications is difficult [8,9].
Given these uncertainties, several studies proposed the use of CT antibody testing as an additional
means to more accurately determine CT lifetime prevalence [1,3,10]. Elevated CT IgG levels in serum
are a marker of a previous CT infection and can provide information on past infection [3,11]. Undetected
and cleared infections can be included in lifetime prevalence estimates and improve the accuracy in
either CT surveillance or in cohort studies assessing the effects of CT infections.
However, the interpretation of CT seropositivity is not straightforward because not all women
with CT infections will develop specific antibodies, furthermore, there is poor insight into the
course of antibody titers, during and after CT infection, and individual variation thereof [1,12,13].
Characteristics of women with and without a positive CT NAAT test who are CT seropositive are
not well-established [3,14]. We wanted to gain more insight into the benefit of CT antibody testing
in estimating CT lifetime prevalence. First, we aimed to assess and compare CT antibody positivity
among women with a CT-positive history (i.e., NAAT-positive results or self-reported positive test
results) and in women with a negative history (NAAT-negative and no self-reported positive test).
Second, we aimed to identify the predictive factors of CT antibody positivity in the two groups.
2. Materials and Methods
2.1. Study Design and Population
We used cross-sectional data from the Netherlands Chlamydia Cohort Study (NECCST), an ongoing
longitudinal cohort study of women of reproductive age in the Netherlands, prospectively followed
for ≥10 years to investigate disease progression of CT [15]. NECCST is a follow-up study from the
Chlamydia Screening Implementation (CSI) study, see Figure 1. In CSI, women were tested annually
for CT through vaginal swabs or urine samples between 2008 and 2011 [16]. Women who participated
in at least one round of CSI were recruited for NECCST in 2015–2016. All participants had ≥1 NAAT
test for CT during CSI, referred to as CSI–NAAT. Between 2008–2011 (CSI) and 2015–2016 (NECCST),
women completed questionnaires about previous CT tests (and results), and on demographics, health
characteristics, and (sexual) risk behavior. At the start of NECCST, capillary blood samples were
collected to test for CT IgG antibodies. Women were included in the present study in case there was a
negative or positive CT IgG antibody result available.
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Figure 1. Flowchart for inclusion of participants in the present study, based on previous participation
in the Chlamydia Screening Implementation (CSI) (n = 58,818) and Netherlands Chlamydia Cohort
Study (NECCST) (n = 5704) projects.
2.2. CT Antibody Testing
Within two weeks after completing the initial NECCST questionnaire, participants received a kit
at home for self-collection of capillary blood for the CT IgG antibody testing. Capillary blood was
obtained via finger prick and collected in a collection tube (BD Microtainer®serum separator tube,
Becton, Dickinson and Company, USA). Samples were sent by regular mail to the laboratory and were
immediately processed and centrifuged, in order to collect the serum. Subsequently, serum samples
were stored at −20 ◦C until the serological measurement was performed [17].
To test for CT antibodies, the commercially available CT IgG ELISA plus (CT IgG ELISA plus;
Medac, Wedel, Germany) test was chosen because this assay is the most widely used serology test in
the Netherlands, which utilizes comparability between studies. In addition, this assay is used in clinics
as part of infertility diagnostics. It is a peptide-based assay and used major outer membrane protein
(MOMP) as the antigen of CT. The synthetic MOMP peptide is based on all available genetic information
of the CT serovar, such that they detect all CT serovars without cross reactivity to other Chlamydiae,
including Chlamydia pneumoniae [18]. This resulted in a high specificity of 97%. Other advantages of the
ELISA plus are the high-throughput and quantitative outcomes [18]. Sensitivity varied between 71–93%
in comparison to the micro-immunofluorescence (MIF) or other serological tests, and between 30–77%
compared to the NAAT-positive women, depending on time since infection [11,18,19]. The assay was
performed according to the anufacturer’s instructions to test for the presence of CT IgG antibodies.
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Quantitative serological outcomes were classified as negative (IgG concentration <22 AU/mL),
grey-zone (IgG concentration 22–28 AU/mL), or positive (IgG concentration ≥28 AU/mL). Samples
with a grey-zone serological outcome were retested and the retest outcome was used. In cases where
the samples tested in the grey-zone again or the samples could not be retested, the participants were
excluded from this study (Figure 1, study flowchart).
2.3. Nucleic Acid Amplification-Based Diagnostics
During the annual CSI, CT tests were performed in self-collected vaginal swabs or urine samples.
These samples were tested by NAATs, which are considered to be the preferred method for diagnosis
of CT infections [4]. In CSI, there was a minimum of one and a maximum of four NAAT outcomes for
all women, depending on participation.
2.4. Questionnaires
Potential predictive factors were obtained by CSI questionnaires and the initial NECCST
questionnaire. CSI questionnaires addressed previous STIs, demographics, and sexual risk behavior.
The NECCST questionnaire contained questions related to CT infections, sexual health, sexual risk
behavior, and health characteristics. In case of at least one self-reported CT infection, the year of the
positive CT test and the CT-related symptoms, such as vaginal discharge, abdominal pain, or pain
during intercourse or intermenstrual vaginal bleeding, were documented. We used CSI data where
possible in order to shorten the recall distance and to verify data.
2.5. CT History
A CT-positive history was determined by positive NAAT outcomes during CSI and self-reported
positive CT tests during CSI or NECCST. A self-reported test was defined as a positive CT test (NAAT)
performed in an STI clinic or hospital, by a GP, or performed in samples collected at home but tested
in a laboratory. A CT-negative history was defined as no positive NAAT result and no self-reported
positive CT tests.
2.6. Potential Predictive Factors
First, demographics were taken into account. Age of participants was assessed at the time of
the initial NECCST questionnaire. Migration background was classified as ‘Western’ if both parents
had a Western country of birth (i.e., a country from Europe [excluding Turkey], North-America,
Oceania, Indonesia, and Japan), ‘non-Western’ if at least one parent had a non-Western country of
birth, and ‘unknown’ if one parent was Western whereas the country of birth of the other parent was
unknown, or when country of birth of both parents was unknown. Educational level was categorized
by low- and middle-educational level versus high-educational level (low/medium—no education,
primary education only, lower general secondary education, and vocational education, high—higher
professional education and university education). Other potential predictive factors were—the number
of CT infections, number of CT tests, years since last infection until the year of the initial NECCST
questionnaire (serum test), CT symptoms (yes/no), and previous gonorrhea infections. Factors related
to sexual risk behavior were—the number of lifetime sex partners, condom use with a casual partner,
condom use with a steady partner, and age of sexual debut. Last, the following health characteristics
were considered—smoking and Body Mass Index (BMI).
2.7. Statistical Analysis
Prior to conducting analyses, the amount of missing data was investigated. In addition, it was
determined whether the missing data were dependent on the participants’ characteristics or the outcome
variable. Descriptive analyses were performed and characteristics of the total study population are
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presented. To compare characteristics between women with a positive and negative chlamydia history,
the chi-squared test, t-tests, and the Wilcoxon rank-sum test were used.
CT antibody status was described and compared by a CT-negative history and a CT-positive
history, using the chi-squared tests. The latter was further divided between CSI-NAAT positive women
and women with self-reported positive CT tests only. The additional value of the CT antibody testing
for estimating CT lifetime prevalence in combination with CT-NAAT and self-reported positive tests
was calculated. Differences in CT lifetime prevalence’s were tested with the McNemar test.
To examine predictive factors of CT antibody positivity, multivariable logistic regression analyses
were performed. The analyses were stratified by CT history (a negative history or a positive history).
Univariable analyses tested associations between potential predictive factors and CT IgG antibody
presence. p-values < 0.10 were used as cut-off for inclusion in the multivariable model. In the
multivariable model, a backward stepwise selection was used in order to manually remove factors
that were not significantly (p ≥ 0.05) associated with CT antibody positivity anymore. Results of
univariable and multivariable analyses were presented as odds ratios (ORs) and adjusted odds ratios
(aORs) with 95% confidence intervals (CIs). Statistical analyses were performed using STATA (Version
15.1; StataCorp, College Station, TX, USA).
2.8. Ethics Approval
This study was approved by the Medical Ethical Committee VU medical Center, Amsterdam the
Netherlands (NL 51553.094.14/2015.903(A2019.336)), date of approval 13 October 2015.
2.9. Data Availability
On request, anonymized data could be provided for research related to STI, after approval by an
advisory committee.
3. Results
In total, 3,702 blood samples were tested for CT antibodies from women who had an available
NAAT result and who completed the initial NECCST questionnaire. Of the 80 grey-zone samples,
32 were excluded from analyses because of insufficient serum volume for retesting or a second
grey-zone test outcome. Additionally, 57 women were excluded because they did not meet the criteria
for CT history positivity resulting in 3,613 women being included in the analyses; see Figure 1. The
amount of missing data was 0.5%. Missing values did not depend on participant characteristics and
were assumed to be at random.
3.1. Participant Characteristics
Table 1 summarizes the main characteristics of all participants, n = 3,613. In total, 2,780
(76.9%) participants had a CT-negative history and 833 (23.1%) participants had a CT-positive history.
Of participants with a CT-positive history, 206 (24.7%) had ≥1 positive CSI–NAAT result and 627
(75.3%) were based on self-reported positive CT tests only. Participants predominantly had a Western
migration background (83.4%), were often highly educated (81.6%), and the mean age was 31.2 (SD 3.8,
range 21–38) years in 2015/2016 at the time of CT IgG antibody test.
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n = 2780 (76.9%)
CT-Positive History ‡




Q1: 21–28 years 923 (25.6) 703 (25.3) 220 (26.4)
Q2: 29–31 years 954 (26.4) 721 (25.9) 233 (28.0)
Q3: 32–34 years 899 (24.9) 685 (24.6) 214 (25.7)
Q4: 35–38 years 837 (23.2) 671 (24.1) 166 (19.9)
Migration background (n (%)) <0.001
Western 3017 (83.5) 2391 (86.0) 626 (75.2)
Non-western 446 (12.3) 277 (10.0) 169 (20.3)
Unknown 150 (4.2) 112 (4.0) 38 (4.6)
Educational level # a (n (%)) <0.001
Low and middle 661 (18.3) 439 (15.8) 222 (26.7)
High 2949 (81.7) 2339 (84.2) 610 (73.3)
Infection characteristics
Number of CT infections (n (%))
0 infections 2780 (76.5) 2,780 (100.0)
1 631 (17.5) 631 (75.8)
2 166 (4.6) 166 (19.9)
≥3 36 (1.0) 36 (4.3)
Number of CT tests (n (%)) <0.001
<2 tests 609 (16.9) 576 (20.7) 33 (4.0)
2 994 (27.5) 852 (30.7) 142 (17.1)
3 968 (26.8) 748 (26.9) 220 (26.4)
>3 1042 (28.8) 604 (21.7) 438 (52.6)
Years since last CT infection b (median IQR) 6.0 (4.0–9.0) 6.0 (4.0–9.0)
CT symptoms c $ (n (%))
No symptoms 408 (49.0) 408 (49.0)
Symptoms 425 (51.0) 425 (51.0)
Sexual behavior
Condom use with steady partner d (n (%)) 0.001
Always, mostly 309 (8.6) 260 (9.4) 49 (5.9)
Sometimes 583 (16.2) 439 (15.9) 144 (17.3)
Never/not often 1000 (27.8) 734 (26.5) 266 (32.0)
At beginning of relationship 1665 (46.2) 1301 (47.0) 364 (43.8)
No steady partners 45 (1.3) 36 (1.3) 9 (1.1)
Condom use with casual partner e (n (%)) <0.001
Always, mostly 1662 (46.1) 1313 (47.4) 349 (42.0)
Sometimes 1131 (31.4) 762 (27.5) 369 (44.4)
Never/not often 217 (6.0) 165 (6.0) 52 (6.3)
No casual partners 592 (16.4) 530 (19.1) 62 (7.5)
Number of lifetime sexual partners (n (%)) <0.001
<6 partners 1163 (32.2) 1034 (37.2) 129 (15.5)
6–12 1243 (34.4) 956 (34.4) 287 (34.5)
>12 1207 (33.4) 790 (28.4) 417 (50.1)
Age of first intercourse (n (%)) <0.001
≤15 years 926 (25.6) 647 (23.3) 279 (33.5)
16–17 1419 (39.3) 1076 (38.7) 343 (41.2)
≥18 1268 (35.1) 1057 (38.0) 211 (25.3)
Self-reported gonorrhea infection (n (%)) <0.001
Never 3555 (98.4) 2758 (99.2) 797 (95.7)
At least one 58 (1.6) 22 (0.8) 36 (4.3)
Smoking status (n (%)) <0.001
Never 1455 (40.3) 1205 (43.3) 250 (30.0)
Occasional 1813 (50.2) 1351 (48.6) 462 (55.5)
Daily 345 (9.6) 224 (8.1) 121 (14.5)





n = 2780 (76.9%)
CT-Positive History ‡
n = 833 (23.1%)
p-Value
Lifestyle characteristics
BMI f (median (IQR))
22.5
(20.8–24.8) 22.5 (20.8–24.6) 22.7 (20.8–25.3) 0.117
Data are medians± inter quartile ranges (IQR) or numbers and percentages. Percentages might not add up to
a total of 100 as values were rounded-up. CT = Chlamydia trachomatis, Q = quartile, BMI = Body Mass Index.
† CT-negative history was defined as: no positive Nucleic Acid Amplification Test (NAAT) result during the
Chlamydia Screening Implementation study (CSI) [16] and no self-reported positive CT test. ‡ CT-positive history
was defined as—at least one NAAT positive result during CSI or self-reported positive CT tests. o Migration
background was classified as ‘Western’ if both parents had a Western country of birth (i.e., a country from Europe
[excluding Turkey], North-America, Oceania, Indonesia, and Japan), ‘non-Western’ if at least one parent had a
non-Western country of birth, and ‘unknown’ if one parent was Western whereas the country of birth of the other
parent was unknown or when country of birth of both parents was unknown. # Educational level was categorized by
low- and middle-educational level versus high-educational level (low/medium—no education, primary education
only, lower general secondary education, and vocational education, high—higher professional education and
university education). $ CT symptoms included—vaginal discharge, abdominal pain or pain during intercourse or
intermenstrual vaginal bleeding. a missing 3. b missing 3: based on women (n = 833) with a CT-positive history.
c based on women (n = 833) with a CT-positive history. d missing 11; e missing 11; f missing 4.
3.2. CT Antibody Status
Table 2 presents CT antibody status stratified by CT history, with a further distinction between
participants with at least one CSI–NAAT positive result and participants with only self-reported
positive CT tests. Of the 2,780 participants with a CT-negative history, 208, i.e., 7.5% (95% CI 6.5–8.5)
tested positive for CT IgG, and among the 833 participants with a CT-positive history, 338, 40.6% (95%
CI 37.2–43.9) tested positive for CT IgG (p < 0.001). CSI–NAAT positives were more often (n = 98,
47.6%, 95% CI 40.6–54.6) CT-IgG-positive, compared to women with only self-reported positive tests
(n = 240, 38.3%, 95% CI 34.5–42.1), p = 0.018.
Table 2. CT IgG antibody status in women with a CT-positive history and a CT-negative history.
CT IgG Positive Total p Value
CT-negative history † 208 (7.5%) 2780 (100%) <0.001 *
CT-positive history ‡ 338 (40.6%) 833 (100%)
NAAT positive in CSI 98 (47.6%) 0.018 **
Self-reported positive 240 (38.3%)
Total 546 (15.1%) 3613 (100%)
CT—Chlamydia trachomatis, IgG—Immunoglobulin G, NAAT—Nucleic Acid Amplification Test, CSI—Chlamydia
Screening Implementation study. † CT-negative history was defined as: no positive NAAT result during the CSI [16]
and no self-reported positive CT test. ‡ CT-positive history was defined as: at least one NAAT positive result during
CSI or self-reported positive CT test. * p value of the difference in CT IgG positivity between CT history negative
and CT history positive women. ** p-value of the difference in CT IgG positivity between CSI–NAAT positives and
self-reported positive tests only.
Including outcomes of the CT antibody tests in the CT history definition (i.e., combining CSI–NAAT
positive tests (n = 206), only the self-reported positive tests (n = 627), and only the CT antibody positives
(n = 208) increased the lifetime CT prevalence from 23.1% (95% CI 21.7–24.5) to 28.8% (95% CI 27.3–30.3).
This was a significant increase of 5.8% (95% CI 5.0–6.5), p < 0.001.
3.3. Predictors of Having CT Antibodies
Table 3 shows univariable associations with CT antibodies and predictive factors of CT antibody
positivity, identified by multivariable analyses. For women with a CT-positive history, multivariable
analysis indicated that only the following factors remains associated with CT antibody positivity:
unknown migration background, higher number of CT infections, and non-smoking.
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Table 3. Univariable and multivariable analyses of Chlamydia trachomatis (CT) IgG antibody status
stratified for women with a CT-negative and a CT-positive history.
Positive CT IgG Antibody Status
CT-Negative History † CT-Positive History ‡
CT IgG Antibody Positivity n/N 207/2768 337/830
Crude Adjusted Crude Adjusted
Variable OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
Age
Q1: 21–28 years * 1 1
Q2: 29–31 years 0.95 (0.63–1.44) 1.11 (0.76–1.63)
Q3: 32–34 years 1.05 (0.70–1.58) 1.09 (0.74–1.60)
Q4: 35–38 years 1.33 (0.90–1.97) 1.27 (0.84–1.91)
Migration background o
Western * 1 1 1 1
Non-Western 2.19 (1.49–3.21) 2.22 (1.49–3.29) 1.47 (1.04–2.06) 1.38 (0.97–1.96)
Unknown 2.03 (1.13–3.64) 2.10 (1.16–3.83) 1.81 (0.94–3.49) 1.98 (1.00–3.91)
Educational level # a
Low and middle * 1 1 1
High 0.50 (0.36–0.70) 0.58 (0.41–0.82) 0.84 (0.61–1.14)
Number of CT infections
1 * 1 1
≥2 2.35 (1.71–3.25) 2.28 (1.64–3.17)
Number of CT tests
<2 tests * 1 1
2 0.77 (0.51–1.17) 1.06 (0.49–2.30)
3 1.07 (0.72–1.61) 0.93 (0.44–1.97)
>3 1.14 (0.75–1.73) 1.11 (0.54–2.30)
Years since last CT infection b
<2 years * 1
2–5 0.73 (0.44–1.21)
>5 0.65 (0.41–1.03)
CT symptoms $ c
No symptoms * 1
Symptoms 1.14 (0.86–1.50)
Condom use with steady partner d
Always, mostly * 1 1
Sometimes 1.10 (0.63–1.95) 1.45 (0.75–2.80)
Never/not often 0.84 (0.49–1.44) 0.96 (0.52–1.79)
At beginning of relationship 0.99 (0.60–1.63) 0.87 (0.47–1.59)
No steady partners 1.10 (0.31–3.87) 1.16 (0.28–4.86)
Condom use with casual partner e
Always, mostly * 1 1
Sometimes 1.32 (0.96–1.82) 0.99 (0.73–1.33)
Never/not often 0.65 (0.31–1.35) 1.00 (0.55–1.81)
No casual partners 0.79 (0.52–1.20) 1.21 (0.71–2.09)
Number of lifetime sexual partners
<6 partners * 1 1 1
6–12 1.68 (1.19–2.39) 1.76 (1.22–2.53) 0.90 (0.58–1.37)
>12 1.64 (1.14–2.37) 1.81 (1.23–2.68) 1.17 (0.78–1.75)
Age at first intercourse
≤15 years * 1 1 1
16–17 0.70 (0.50–0.98) 0.75 (0.53–1.07) 0.83 (0.60–1.15)
≥18 0.56 (0.39–0.80) 0.62 (0.42–0.90) 0.96 (0.67–1.38)
Self-reported gonorrhea infection
Never * 1 1
At least one 2.78 (0.93–8.30) 2.11 (1.08–4.17)
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Table 3. Cont.
Positive CT IgG Antibody Status
CT-Negative History † CT-Positive History ‡
CT IgG Antibody Positivity n/N 207/2768 337/830
Crude Adjusted Crude Adjusted
Variable OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI)
Smoking status
Never * 1 1 1
Occasional 1.07 (0.79–1.45) 0.73 (0.54–1.00) 0.70 (0.51–0.97)
Daily 1.96 (1.24–3.08) 1.36 (0.88–2.10) 1.17 (0.75–1.84)
BMI f
Healthy weight (18.5–25) * 1 1 1
Underweight (<18.5) 0.76 (0.27–2.11) 0.76 (0.27–2.14) 0.58 (0.24–1.40)
Overweight (25–30) 1.15 (0.78–1.69) 1.09 (0.73–1.62) 1.19 (0.83–1.69)
Obese (≥30) 2.33 (1.49–3.65) 1.81 (1.13–2.91) 1.81 (1.10–2.97)
OR—odds ratio, aOR—adjusted odds ratio, CI—confidence interval, CT—Chlamydia trachomatis,
IgG—Immunoglobulin G, Q—quartile, BMI—Body Mass Index. Factors associated (p < 0.10) in the univariable
analyses were included in the multivariable analysis. Significant (p < 0.05) results are presented in bold. * Reference
category. † CT-Negative history was defined as ‘no positive Nucleic Acid Amplification Test (NAAT) result during
the Chlamydia Screening Implementation study (CSI) [16] and no self-reported positive CT tests’. ‡ CT-Positive
history was defined as ‘at least one NAAT positive result during CSI or self-reported positive CT test’. o Migration
background was classified as ‘Western’ if both parents had a Western country of birth (i.e., a country from Europe
[excluding Turkey], North-America, Oceania, Indonesia, and Japan), ‘non-Western’ if at least one parent had a
non-Western country of birth, and ‘unknown’ if one parent was Western whereas the country of birth of the other
parent was unknown or when country of birth of both parents was unknown. # Educational level was categorized
by low- and middle-educational level versus high-educational (low/medium—no education, primary education
only, lower general secondary education, and vocational education, high—higher professional education and
university education). $ CT symptoms included—vaginal discharge, abdominal pain or pain during intercourse or
intermenstrual vaginal bleeding. a missing 3. b missing 3—based on women (n = 833) with a CT-positive history.
c based on women (n = 833) with a CT-positive history. d missing 11. e missing 11. f missing 4.
For women with a CT-negative history, multivariable analysis demonstrated that the
predictive factors of CT antibody positivity were non-Western or unknown migration background,
low/middle-educational level, higher number of lifetime sexual partners, younger age at first intercourse,
and BMI > 30.
4. Discussion
In this cohort of women of reproductive age, eight percent of women who previously tested
negative for CT by NAAT, tested positive for CT IgG antibodies. This increased the CT lifetime
prevalence estimate with six percent. Among women who previously tested positive for CT by NAAT,
40% tested positive for the CT IgG antibodies. In women with a CT-positive history (CSI–NAAT
positive or self-reported positive CT tests), the predictive factors of CT antibody positivity were an
unknown migration background and multiple CT infections, while occasional smoking (compared
to current smoking) had a preventive effect. In women with a CT-negative history, predictive
factors of previous unnoticed infections were a non-Western and unknown migration background,
low- or middle-educational level, higher number of lifetime sexual partners, younger age at first sexual
intercourse, and obesity.
CT IgG antibody testing identified 208 unnoticed CT infections among 2,780 women; infections
that otherwise would have been missed. Therefore, in this population of women with a mean age
of 31 (SD 4), lifetime CT prevalence increased by six percent from 23% (i.e., CSI–NAAT positive or
self-reported positive tests) to 29%, including CT antibody testing. Although an increase of six percent
suggests only a minor increase, the 208 additional CT history positives accounted for twenty percent
(208/1,041) of all CT history positives. This was similar for CSI–NAAT positives that also accounted for
20% (206/1,041) of CT history positives, whereas the contribution from self-reported positive CT tests
was 60%. Focusing only on NAAT and self-reported tests has its limitations. Although NAATs are
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highly sensitive and specific [4], only current CT infections can be measured. Median number of NAAT
tests per participant in CSI was two. Including only NAAT outcomes for the CT lifetime prevalence
would result in a large underestimation. Self-reported positive tests contributed the most in CT lifetime
prevalence estimates, but might have induced recall bias and resulted in misclassifications in CT history.
This was demonstrated in the difference in CT antibodies among women with a CSI–NAAT positive
result (48% CT IgG positive) and women who only had a self-reported positive test (38% CT IgG
positive). Therefore, combining NAAT outcomes, self-reported positive test outcomes, and CT antibody
test outcomes results in more robust prevalence estimates. This would not erase misclassification but
would reduce it. Consequently, estimation of the proportion of women who experiences CT-related
complications, for example in cohort studies, would be more precise by including IgG antibody testing
because there would be less misclassification in CT status [1,20].
Nevertheless, among women with a positive NAAT, less than half tested positive for CT IgG
antibodies. Therefore, the proportion of women with past CT infections is presumably higher. Among
CT- positive history women, 60% of infections were missed while using antibody testing. Assuming a
similar test sensitivity in both the CT- positive and CT-negative group, and by applying this percentage
missed to the CT- negative group, one could hypothesize that true CT (sero-) positivity is around 20%
instead of 8% in the CT- negative group. However, sensitivity might differ between these two groups
as in the CT- positive group, 51% of women reported symptoms and 24% of women had multiple CT
infections, which could have caused higher antibody responses [11,21].
In participants with a CT-positive history, an unknown migration background and multiple CT
infections were strongly associated with CT antibody positivity. This provides additional evidence
that repeated exposure to CT infections is an important predictor of CT antibody positivity [11,22].
Occasional smoking compared to non-smoking was demonstrated to be a condition that decreases
the likelihood of having CT IgG antibodies. We only found this association among women who
previously tested positive for CT. It is, therefore, not a risk or protective factor for acquiring a CT
infection, but specifically in having CT IgG antibodies following CT infection. The association might
be explained by alterations in the immune response, such as an accelerated decrease of antibodies
over time or weaker antibody responses. It is known that smoking can downregulate the immune
system [23]. However, we did not find a significant difference with current smokers as compared
to non-smokers.
In participants with a CT-negative history, predictive factors for antibody positivity could
be interpreted as predictive factors for women with unnoticed infections next to predictors for
seroconversion. A non-Western or unknown migration background and low/middle-educational level
were predictive for antibody positivity [24,25] and both characteristics related to a lower socioeconomic
status (SES), which was associated with increased sexual risk behavior [26]. Additionally, previous
research found higher CT antibody responses among African-Americans compared to Caucasians [13].
A positive association was found between a high number of lifetime sexual partners and CT antibody
positivity, although this association was less strong than demonstrated in a previous study [10]. Age at
time of antibody test was not a risk factor for having antibodies, probably because the majority
of women in the cohort were all around thirty years of age. However, younger age at first sexual
intercourse also increased the risk of being CT antibody positive and was consistent with previous
research [10,27]. Young age is a consistent risk factor for CT acquisition, which could suggest an
acquired and protective immune response [28]. Moreover, women with obesity had an increased
risk of being CT antibody positive. We do not have a clear explanation for this finding. Although
obesity is a condition that affects those with a low SES more often [29], the association remained after
correcting for education level and migration status in the multivariable model. This suggests that a
lower SES is not an explanation for this finding. On the other hand, we cannot completely rule out
residual confounding. It might be that BMI is not completely explained by the variables we have in
the dataset and that BMI is still linked to a lower SES and, therefore, poses a higher risk for acquiring
CT infection and not specifically CT IgG antibodies. Especially because obesity is associated with
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impaired immunity and reduced immunocompetence [30], we would expect to find a decreased risk
for CT antibodies instead of an increased risk. It would be interesting to study a possible association
between CT infection or presence of CT antibodies and BMI in other cohorts. Last, participants with
a CT-negative history and a positive CT antibody test presumably did not receive treatment for the
infection. This IgG test does not give any information on whether the infection was past or current.
Hence, treatment is not indicated, which is in line with national and international guidelines [31].
Several limitations should be noted. The antibody test specificity (although high—97%) could,
in combination with the low seroprevalence in the CT- negative group, result in a considerable
number of false positives. However, the specificity issues reported in general in the past based
on the potential cross reactivity with Chlamydia pneumoniae, Chlamydia psittaci, and Acinetobacter
were not applicable in the current peptide-based ELISA from Medac in which a small peptide from
the MOMP protein was selected with no cross reactivity with C. pneumoniae, in contrast to either
lipopolysaccharide-based ELISAs or total MOMP-based ones [32–34]. Furthermore, there was the
possibility of selection bias. The overall CT antibody positivity rate of 16% found in this study was
higher than that found in a population-based seroprevalence study among 25–39-year old women,
which was previously conducted in the Netherlands; a seroprevalence of 9% in 2007 was found [14].
A possible explanation might be that NECCST participants were at higher risk for CT when compared
to the general population who participated in the population-based study. This was also seen in the
screening trial. CSI participants had a higher CT positivity rate compared to the estimated population
prevalence and had higher behavioral risk factors compared to people not participating in the CSI,
which suggest a self-selection for screening, based on personal risk perception [16,35]. This might
influence the generalizability of the results. The 8% antibody positives in the CT-negative group could
be an overestimation when compared to the general population.
To gain more insight into the proportion of women with unnoticed previous CT infections
and thereby improve the prevalence estimates even more, further research should be conducted.
For example, assays based on different CT antigens such as the Pgp3 in combination with MOMP-based
assays or assays using a range of CT antigens to determine the most reactive CT antigens might increase
insight [12,36,37]. Additionally, the effect of time on antibody levels requires further study. In our
multivariable analyses, time measured in years, since last infection was not a predictive factor for CT
antibody positivity in multivariable analysis. According to a study by Horner et al. [11], antibodies
were detected in only 38% of participants from genitourinary medicine clinics six months after infection,
as compared to 77% at time of infection, using the ELISA plus from Medac [19,21]. This suggests
that the antibody levels decreased within the first months after infection, but no significant further
reduction happened after six months. This was comparable with a recent study in which the same
assay was used, antibodies were measured within three months and three to ten years after infection;
seroprevalence was 66% and 35%, respectively [22].
In conclusion, we demonstrated that CT IgG antibody testing identified women with unnoticed CT
infections among women previously tested negative for CT by NAAT. Although not all women tested
positive for CT antibodies despite a previous CT infection, the extra infections found with antibody
testing significantly increased the CT lifetime prevalence estimates. Consequently, this improved the
estimates on proportions of women who experienced CT-related complications. In estimating the CT
lifetime prevalence, we recommended CT antibody testing in combination with previous chlamydia
test outcomes.
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